.svg)
.svg)
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg){kind=icon}
.svg){kind=icon}
Publication date: September 3, 2025
Siemens Healthineers AG is a leading German medical technology company focused on diagnostic systems, imaging and medical software. Investors follow this stock closely because of its robust revenue growth and strong position in the fast-growing healthcare market. In this article, you can read all about the current share price, expectations and why Siemens Healthineers could be interesting for your investment portfolio. Would you like to receive weekly updates on European equities? Subscribe here to our newsletter and stay informed.
.webp)
- Year of establishment: 2017 (split off Siemens AG)
- Year added to the DAX 40: 2021
-Highest price ever: €67.66 December 2021
- Average trading volume: 708.78 thousand shares per day
- Price performance over the past 12 months: -11,28%
Introduction about the company
Siemens Healthineers AG was listed independently in 2017 after the medical technology division of Siemens was spun off. Headquartered in Erlangen, Germany, the company serves hospitals, diagnostic centers and research laboratories worldwide. Its portfolio includes MRI and CT scanners, laboratory equipment, molecular diagnostics and oncology solutions.
Key figures & performance
In fiscal 2024, Siemens Healthineers achieved sales of €21.39 billion, further strengthening its position as one of the leading medical technology companies in Europe. Net profit rose to €2.59 billion, an increase of about 29% compared with the previous year. This increase reflects the successful integration of previous acquisitions, including Varian Medical Systems, and solid growth within the imaging and laboratory divisions. In particular, demand for advanced MRI and CT solutions, as well as laboratory diagnostics, contributed to earnings growth. The operating margin improved slightly, despite cost increases within production and R&D.
In July 2025, the market capitalization was €53.68 billion, placing Siemens Healthineers among the stable, mid-sized core players within the DAX 40. The company manages to maintain its market value well, despite temporary share price declines due to geopolitical uncertainties and cautious investments in the Chinese healthcare market. Nevertheless, its financial profile remains strong, supported by solid cash flows and a profitable growth model.
History & development
Siemens Healthineers began in 2017 as an independent company separate from Siemens AG, which initially retained a majority stake. The company led a series of strategic acquisitions, including the acquisition of Varian Medical Systems in 2020. Since then, the company has continued to expand its pipeline and services. Despite challenges, such as reduced demand in China, Siemens Healthineers is raising its profile in diagnostic imaging and clinical laboratories.
Sector & competition
The company operates in the medical technology industry, competing with players such as GE Healthcare, Philips and Roche Diagnostics. Diversification across segments such as diagnostics, imaging and therapy provides a solid foundation. With technologies such as PET-CT scanners, molecular diagnostics and lab automation, Siemens Healthineers stands out in a sector with high innovation and entry rates.
Influence of Siemens Healthineers on the DAX 40
Since its inclusion in the DAX 40 in 2021, Siemens Healthineers has become a medium-sized but stable player within the index. With an index weighting of 1.02% in December 2024, the stock has a modest but constant influence on the Healthcare & Technology segment. Thanks to the combination of a solid dividend policy and continuous investment in medical innovation, the company remains a relevant name within the German main index. View the composition of the DAX 40 and the weighting of all companies in the DAX 40 here.
Investment analysis & outlook
The price chart clearly shows that Siemens Healthineers lost about 11% in market capitalization over the past 12 months, while the DAX rose sharply over the same period. The share price peaked at €67.66 in December 2021, but since then has steadily declined, partly due to decreased demand in China and pressure on diagnostics sales. In fiscal 2024, however, the company managed to post revenues of €22.36 billion, with a net profit of €1.94 billion, indicating a stable operating base. The chart recently shows a phase of sideways consolidation around a key support level, which may indicate bottom formation. The strategic focus is on growth in AI-driven medical imaging, laboratory automation and oncology applications. Sales growth of 5-6% is forecast for 2025 and earnings per share between €2.35 and €2.50. Despite the weak share price performance, the combination of technological innovation, defensive positioning and dividend yield may offer an interesting entry point for long-term investors.
News & updates
Recently, the company highlighted its strategy toward AI-driven diagnostics and oncology tools. At the same time, the board announced a dividend of €0.95 per share, in line with previous years. The announced growth forecast and a stabilized EBIT margin give confidence for investor strategy.
Disclaimer: Investing involves risks. Our analysts are not financial advisors. Always consult an advisor when making financial decisions. The information and tips provided on this website are based on our analysts' own insights and experiences. They are therefore for educational purposes only.
.webp)
.webp)
.webp)
.webp)
